Jazz Pharmaceuticals (JAZZ) Raw Materials (2010 - 2019)

Jazz Pharmaceuticals (JAZZ) posted quarterly Raw Materials of $7.1 million for Q1 2019, up 27.37% quarter-over-quarter from $5.6 million in Q4 2018.

Jazz Pharmaceuticals (JAZZ) Raw Materials (2010 - 2019) Analysis & Trends

Jazz Pharmaceuticals' Raw Materials history runs 10 years deep, the most recent figure standing at $7.1 million for Q1 2019.

In Q1 2019, Raw Materials changed N/A year-over-year to $7.1 million; the TTM figure through Mar 2019 stood at $7.1 million (changed N/A YoY), while the FY2018 annual figure was $5.6 million, up 58.22% from the prior year.
Raw Materials for Q1 2019 stood at $7.1 million, up from $5.6 million in the prior quarter.
The five-year high for Raw Materials was $7.1 million in Q1 2019, with the low at $1.5 million in Q4 2016.
The 5-year median for Raw Materials is $2.7 million (2016), against an average of $3.6 million.
The sharpest annual moves came in 2016 and 2017: Raw Materials sank 40.68% in 2016, then surged 128.96% in 2017.
Jazz Pharmaceuticals' Raw Materials stood at $2.6 million in 2015, then tumbled by 40.68% to $1.5 million in 2016, then surged by 128.96% to $3.5 million in 2017, then jumped by 58.22% to $5.6 million in 2018, then gained by 27.37% to $7.1 million in 2019.
Business Quant data shows JAZZ's Raw Materials at $7.1 million in Q1 2019, $5.6 million in Q4 2018, and $4.2 million in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Jazz Pharmaceuticals	15.90 Bn	14.28 Bn	1.09 Bn

Download Data